Eftozanermin alfa

依托奈明α

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEftozanermin alfa
Drug Alias NameEftozaAPG-350APG-880ABBV-621PR-1625011
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTNF-related apoptosis-inducing ligand receptors agonists
TargetsTNF-related apoptosis-inducing ligand receptors
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsMultiple Myeloma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsItaly +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsMultiple MyelomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A